Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R. Brown, Mazyar Shadman, Susan O’Brien et al.|New England Journal of Medicine|2022Cited by 453
Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)Jennifer R. Brown, Mazyar Shadman, Barbara Eichhorst et al.|Blood|2023Cited by 24
Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Mary Ann Anderson et al.|Blood Advances|2025Cited by 2